Exact Sciences Corporation (EXAS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 66.85 |
| Open | 66.58 |
| Bid | 65.00 x 1000 |
| Ask | 65.89 x 1100 |
| Day's Range | 65.73 - 67.35 |
| 52 Week Range | 29.27 - 100.77 |
| Volume | |
| Avg. Volume | 1,349,414 |
| Market Cap | 11.913B |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.33 |
| Earnings Date | Nov 01, 2023 - Nov 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 111.47 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for EXAS
Related Research
- Exact Sciences CorporationAnalyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening.RatingFair ValueEconomic Moat2 months agoMorningstar
- Investing.com
Uranium ETF shines while ARK Genomic Revolution ETF struggles
In a striking contrast of fortunes in the Exchange-Traded Fund (ETF) market on Friday, the Uranium ETF outperformed its peers, while the ARK Genomic Revolution ETF struggled.
Business WireAgilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
SANTA CLARA, Calif. & MADISON, Wis., September 12, 2023--Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party.
Motley FoolWhere Will Exact Sciences Be in 5 Years?
Over the past five years, Exact Sciences (NASDAQ: EXAS) hasn't delivered great returns. Exact Sciences develops cancer diagnostic tests. It is best known for its at-home, noninvasive colorectal cancer screening option, Cologuard.
